Form 8-K - Current report:
SEC Accession No. 0001714899-20-000099
Filing Date
2020-08-20
Accepted
2020-08-20 16:34:43
Documents
14
Period of Report
2020-08-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20200817.htm   iXBRL 8-K 54342
  Complete submission text file 0001714899-20-000099.txt   196962

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20200817.xsd EX-101.SCH 2453
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20200817_cal.xml EX-101.CAL 730
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20200817_def.xml EX-101.DEF 1663
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20200817_lab.xml EX-101.LAB 23970
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20200817_pre.xml EX-101.PRE 12666
7 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20200817_htm.xml XML 10822
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 201120409
SIC: 2836 Biological Products, (No Diagnostic Substances)